Lupin launches antidepressant drug Fluoxetine in US market

The company has launched its Fluoxetine tablets USP in the strength of 60mg after having received approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.

Mumbai: Drug firm Lupin Wednesday said it has launched generic antidepressant Fluoxetine tablets in the American market.

The company has launched its Fluoxetine tablets USP in the strength of 60mg after having received approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.

Also Read: Lupin recalls over 12000 cartons of Fayosim from US market

The product is the generic version of Alvogen Group Holdings 3 LLC's Fluoxetine tablets in the same strength, it added.

As per IQVIA MAT February 2019 data, Fluoxetine tablets 60mg had annual sales of around USD 41 million in the US, Lupin said.

The tablets are indicated for treatment of major depressive disorder, obsessive compulsive disorder, bulimia nervosa and panic disorder with or without agoraphobia, it added.

Also Read: USFDA completes inspection of Lupin Bioresearch Centre Pune